NHS drugs could be bought on a value-based approach if proposals from the government are approved.
The plans are at the core of a new system for regulating the prices of branded medicines dependant on thresholds or maximum prices that reflect a broader range of factors than present. These maximum prices would increase for medicines that: tackle diseases where there is a greater "burden of illness," show greater therapeutic innovation and improvements, and provide wider societal benefits. It will succeed the current purchasing agreement that expires at the end of 2013 and branded medicines already covered by the present regulations will be placed under a successor scheme sitting alo...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
